Flush it out: electronic health records hint at diuretics treating Alzheimer’s disease

Written by Darcy Hodge, Editor


Researchers may have found new potential for a diuretic to treat Alzheimer’s disease (AD). The team, from the University of California (CA, USA), utilized real-world evidence including human brain databases. The findings have been published in Nature Aging. The diuretic, known as bumetanide, is a commonly prescribed drug already approved by the FDA. Other available drugs have previously been repurposed for alternative conditions and is an aim of the National Institute of Health (NIH, MA, USA) with their precision medicine approach.  Real-world data was analyzed to identify pre-approved drugs suitable for treating the neurological disease.  Data sources included a collection of 213 brain tissue samples from the Gene Expression Omnibus. One prevalent genetic risk factor for AD includes the apolipoprotein E gene APOE4. Using this information, the common pattern of gene expression associated with the disease, transcriptomic signatures,...

To view this content, please register now for access

It's completely free